Catalyst Pharmaceutical Partners (CPRX)

[DonShimoda]

hi dough, yeah, like ARIA, CPRX's second drug, CPP115, is the ultimate value driver here. The big risk with CPP109 is that the phase 2a trial did not reach it's primary endpoint which makes the phase 2b trial all the more important. There are a couple of reasons why I'm willing to hold the stock now. First, digging a little deeper into the failed P2a trial, it appears the results reflected a poor trial design more than an actual failure of the drug itself. Fewer than 40% of patients took the correct dosage. The trial ended up being severely underpowered and consequently did not meet its endpoint. However, if you break out the results for the pts who did take the drug correctly, the trial would have met its endpoint.